Genomma Lab Internacional, S.A.B. de C.V.
GNMLF
$0.83
-$0.03-3.49%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 251.24M | 231.53M | 219.50M | 238.53M | 239.80M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 251.24M | 231.53M | 219.50M | 238.53M | 239.80M |
| Cost of Revenue | 89.05M | 84.70M | 85.66M | 86.21M | 87.53M |
| Gross Profit | 162.19M | 146.83M | 133.83M | 152.32M | 152.27M |
| SG&A Expenses | 112.31M | 98.60M | 86.77M | 103.68M | 100.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -238.30K | -79.50K | 3.04M | -3.33M | -1.38M |
| Total Operating Expenses | 201.12M | 183.22M | 175.48M | 186.56M | 186.95M |
| Operating Income | 50.12M | 48.31M | 44.02M | 51.97M | 52.85M |
| Income Before Tax | 30.55M | 35.59M | 31.05M | 32.63M | 28.55M |
| Income Tax Expenses | 9.16M | 8.26M | 13.22M | 9.32M | 10.35M |
| Earnings from Continuing Operations | 21.40M | 27.33M | 17.83M | 23.31M | 18.20M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.40M | 27.33M | 17.83M | 23.31M | 18.20M |
| EBIT | 50.12M | 48.31M | 44.02M | 51.97M | 52.85M |
| EBITDA | 55.29M | 53.32M | 49.20M | 57.09M | 57.57M |
| EPS Basic | 0.02 | 0.03 | 0.02 | 0.02 | 0.02 |
| Normalized Basic EPS | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| EPS Diluted | 0.02 | 0.03 | 0.02 | 0.02 | 0.02 |
| Normalized Diluted EPS | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Average Basic Shares Outstanding | 985.51M | 969.90M | 978.15M | 986.51M | 970.10M |
| Average Diluted Shares Outstanding | 985.51M | 969.90M | 978.15M | 986.51M | 970.10M |
| Dividend Per Share | -- | 0.01 | 0.01 | 0.01 | 0.01 |
| Payout Ratio | 52.07% | 39.49% | 59.88% | 90.08% | 0.00% |